| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 34,928 | 37,437 | 32,298 | 44,812 |
| Short-term marketable securities | 128,846 | 148,412 | 156,566 | 159,299 |
| Short-term restricted cash | NaN | NaN | 0 | 0 |
| Accounts receivable | 7,809 | 8,493 | 6,882 | 8,333 |
| Prepaid expenses and other current assets | 6,810 | 4,342 | 8,590 | 10,240 |
| Income tax receivable | 19 | NaN | 0 | 24 |
| Total current assets | 178,412 | 198,684 | 204,336 | 222,708 |
| Property and equipment | NaN | NaN | 59,200 | NaN |
| Less accumulated depreciation and amortization | NaN | NaN | 23,805 | NaN |
| Long-term marketable securities | 63,238 | 56,055 | NaN | NaN |
| Property and equipment, net | 33,114 | 34,308 | 35,395 | 36,617 |
| Operating lease, right-of-use assets | 36,436 | 37,003 | 37,549 | 38,250 |
| Long-term restricted cash | 3,360 | 3,360 | 3,360 | 3,360 |
| Other long-term assets | 144 | 93 | 92 | 94 |
| Total assets | 314,704 | 329,503 | 280,732 | 301,029 |
| Accounts payable | 4,363 | 1,885 | 1,948 | 3,547 |
| Accrued expenses and other current liabilities | 6,859 | 7,575 | 12,751 | 10,853 |
| Liability related to the sale of future royalties | 31,461 | 31,981 | 30,710 | 27,755 |
| Operating lease liabilities | 3,759 | 3,287 | 3,146 | 2,394 |
| Total current liabilities | 46,442 | 44,728 | 48,555 | 44,549 |
| Liability related to the sale of future royalties, net of current portion | 97,309 | 102,822 | 111,132 | 119,943 |
| Operating lease liabilities, net of current portion | 52,777 | 53,782 | 54,757 | 55,656 |
| Series 1 nonconvertible preferred stock | 1,311 | 1,311 | 1,311 | 1,350 |
| Other long-term liabilities | 278 | 269 | 260 | 252 |
| Total liabilities | 198,117 | 202,912 | 216,015 | 221,750 |
| Common stock 0.01 par value per share, 100,000 shares authorized 29,061 and 21,387 shares issued and outstanding at march 31, 2026 and september 30, 2025 respectively | 291 | 290 | 214 | 214 |
| Additional paid-in capital | 546,988 | 543,497 | 469,771 | 465,696 |
| Accumulated other comprehensive loss | -734 | -329 | -339 | -402 |
| Accumulated deficit | -429,958 | -416,867 | -404,929 | -386,229 |
| Total stockholders' equity | 116,587 | 126,591 | 64,717 | 79,279 |
| Total liabilities and stockholders' equity | 314,704 | 329,503 | 280,732 | 301,029 |
ENANTA PHARMACEUTICALS INC (ENTA)
ENANTA PHARMACEUTICALS INC (ENTA)